Online inquiry

IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13509MR)

This product GTTS-WQ13509MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets SNCA gene. The antibody can be applied in Parkinson's disease (PD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000345.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6622
UniProt ID P37840
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13509MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4725MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BOS161721
GTTS-WQ12694MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ4982MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA C4G1
GTTS-WQ11994MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MM-121
GTTS-WQ6916MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ13046MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ9802MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JS002
GTTS-WQ13869MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1979
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW